• KOL
    • Prostate Cancer
    • Howard I Scher
    • Howard I Scher: Influence Statistics

      Howard I Scher

      Howard I Scher

      Show email address

      Memorial Sloan Kettering Cancer Center, New York, NY; | Department of Medicine, Weill Cornell Medical College, New York, NY, USA | Genitourinary Oncology Service, Memorial ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Howard I Scher:Expert Impact

      Concepts for whichHoward I Scherhas direct influence:Prostate cancer,Abiraterone acetate,Androgen receptor,Resistant prostate,Tumor cells,Metastatic prostate cancer,Metastatic castration.

      Howard I Scher:KOL impact

      Concepts related to the work of other authors for whichfor which Howard I Scher has influence:Prostate cancer,Tumor cells,Androgen receptor,Gene expression,Prostatic neoplasms,Bone metastases,Abiraterone acetate.

      KOL Resume for Howard I Scher

      Year
      2022

      Memorial Sloan Kettering Cancer Center, New York, NY;

      Department of Medicine, Weill Cornell Medical College, New York, NY, USA

      2021

      Memorial Sloan Kettering Cancer Center, New York, New York.

      Prostate Cancer Clinical Trials Consortium, New York, NY, USA

      2020

      Weill Cornell Medical College, New York, NY, USA.

      Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA

      Memorial Sloan Kettering Cancer Center, New York, NY, Parexel, Durham, NC.

      2019

      Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address:

      Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

      Weill Cornell Medical College, 407 E 61st St, New York, NY 10065, USA

      2018

      Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA

      Department of Medicine, Weill Cornell Medical College, New York, United States

      2017

      Sloan Kettering Institute, New York, New York

      2016

      Department of Medicine, Weill Cornell Medical College, New York, NY

      From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

      Memorial Sloan‐Kettering Cancer Center New York New York

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Howard I Scher is among the top experts in the world.
      Concept World rank
      fdg plateau #1
      enzalutamide multivariate analysis #1
      fdht fdg pet #1
      noncastrate metastases rp #1
      psma egfr #1
      prolonged adjhr #1
      suv psa #1
      weekly paclitaxel 100 #1
      mvac rhgcsf #1
      psa pcr pcr #1
      hydrocortisone suramin #1
      t878a #1
      pcwg criteria association #1
      rhg csf chemotherapy #1
      cisplatin vac #1
      doseintense mvac #1
      17aag adult patients #1
      desoxyderivatives #1
      adnatest assay #1
      prednisone reported fatigue #1
      undetectable levels patients #1
      neoadjuvant estramustine vinblastine #1
      potency dcs #1
      progressive androgen #1
      patients crmpc #1
      progressive crpc #1
      ttpp ccu #1
      rapid screening distress #1
      usual symptom monitoring #1
      adnatest cellsearch #1
      ttp rtpcr psa #1
      prednisone serum androgens #1
      discontinuation antiandrogen #1
      90–120mg #1
      mortality pccs #1
      intense relative #1
      aap bcr #1
      ctc psa #1
      molecular imaging araxis #1
      arsi #1
      growth rates treatment #1
      lpd analyses #1
      undetectable psa 8 #1
      reported fatigue prednisone #1
      clinical benefit aa #1
      araxis crpc #1
      tumor cells crpc #1
      tmprss2erg status ctcs #1
      cabozantinib mitoxantrone prednisone #1
      axis imaging crpc #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Howard I Scher

      KOL-Index: 19503

      BACKGROUND: Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor signalling pathways implicated in the progression of the disease, including bone metastases. We assessed data for pain control and skeletal-related events prospectively collected as part of the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus prednisone in patients ...

      Known for Abiraterone Acetate | Prednisone Patients | Pain Control | Metastatic Castration | Skeletalrelated Events
      KOL-Index: 19176

      BACKGROUND: In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo. Here we present the prospectively defined analyses of some secondary endpoints, including occurrence of skeletal-related events, measures of pain control, and patient-reported health-related quality of life (HRQoL).

      METHODS: In this phase 3, double-blind trial, patients ...

      Known for Enzalutamide Placebo | Resistant Prostate | 95 P0·0001 | Affirm Trial | Time Deterioration
      KOL-Index: 18707

      BACKGROUND: Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).

      METHODS: Between May 8, 2008, and July 28, 2009, this study enrolled 1195 patients at 147 sites in 13 countries. Patients were ...

      Known for Abiraterone Acetate | Placebo Prednisone | 3 Study | Metastatic Castration | Resistant Prostate
      KOL-Index: 17714

      BACKGROUND: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.

      OBJECTIVE: Report the prespecified third interim analysis (IA) of efficacy and safety outcomes in study COU-AA-302.

      DESIGN, ...

      Known for Abiraterone Acetate | Prednisone Patients | Metastatic Castration | Prior Chemotherapy | Resistant Prostate
      KOL-Index: 17208

      BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.

      OBJECTIVE: To present the results from the APCCC 2019.

      DESIGN, SETTING, AND PARTICIPANTS: Similar to ...

      Known for Advanced Prostate Cancer | Consensus Conference | Management Patients | Molecular Characterisation | Voting Panel
      KOL-Index: 16876

      Genistein is a dietary-derived plant product that inhibits the activity of protein-tyrosine kinases. We show here that it is a potent inhibitor of the mammalian facilitative hexose transporter GLUT1. In human HL-60 cells, which express GLUT1, genistein inhibited the transport of dehydroascorbic acid, deoxyglucose, and methylglucose in a dose-dependent manner. Transport was not affected by daidzein, an inactive genistein analog that does not inhibit protein-tyrosine kinase activity, or by ...

      Known for Dehydroascorbic Acid | Glucose Transporter | Cells Hexoses | Proteintyrosine Kinases | Binding Competitive
      KOL-Index: 16488

      BACKGROUND: Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel chemotherapy.

      METHODS: We did a multicentre, randomised, double-blind, phase 3 trial in which men with at least one bone metastasis from castration-resistant prostate cancer that had progressed ...

      Known for Ipilimumab Placebo | 3 Trial | Radiotherapy Patients | Docetaxel Chemotherapy | Resistant Prostate
      KOL-Index: 15561

      BACKGROUND: Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

      METHODS: In this phase 3, double-blind, placebo-controlled trial, we recruited patients with progressive metastatic castration-resistant prostate cancer and no previous ...

      Known for Resistant Prostate | Placebo Prednisone | Patients Orteronel | Phase 3 | Metastatic Castration
      KOL-Index: 15484

      PURPOSE: The role of postchemotherapy surgery for patients with metastatic transitional cell carcinoma (TCC) is controversial. We retrospectively analyzed our experience with patients who underwent postchemotherapy surgery after methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) chemotherapy to assess an impact on long-term survival.

      PATIENTS AND METHODS: This report is based on the retrospective analysis of 203 patients with unresectable primary tumors or metastatic TCC, ...

      Known for Chemotherapy Surgery | Transitional Cell | Complete Response | Methotrexate Vinblastine | 30 Patients
      KOL-Index: 14883

      Importance: A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a taxane.

      Objective: To determine if pretherapy nuclear androgen-receptor splice variant 7 (AR-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific marker for response and outcomes between ARS inhibitors and taxanes.

      Design, Setting, and Participants: For this ...

      Known for Tumor Cells | Resistant Prostate | Taxane Therapy | Mcrpc Androgen Receptor | Arv7positive Ctcs
      KOL-Index: 14793

      BACKGROUND: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.

      METHODS: In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 men with castration-resistant prostate cancer after chemotherapy according to the Eastern Cooperative Oncology Group ...

      Known for Prostate Cancer | Hazard Ratio | Increased Survival | Enzalutamide Placebo | P0001 Time
      KOL-Index: 14774

      The M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) regimen was used to treat 25 patients with transitional cell carcinoma of the urothelial tract. Treatment consisted of monthly cycles of 30 mg. per m.2 methotrexate, followed 24 hours later by 3 mg. per m.2 vinblastine, 30 mg. per m.2 doxorubicin and 70 mg. per m.2 cisplatin, and concluded with repeat vinblastine and methotrexate on days 15 and 22. Significant tumor regression was noted in 71 per cent of the patients. ...

      Known for Transitional Cell Carcinoma | Methotrexate Vinblastine | Doxorubicin Cisplatin | Cent Patients | 4 Months
      KOL-Index: 14459

      BACKGROUND: Biomarkers based on detecting prostate cancer (PCa)-specific transcripts in blood are associated with inferior outcomes, but their validation in a clinical context is lacking.

      OBJECTIVE: To determine whether detecting enhanced transcripts for PCa in whole blood using an analytically valid assay has prognostic significance relative to circulating tumor cell (CTC) enumeration.

      DESIGN, SETTING, AND PARTICIPANTS: The detection of KLK3, KLK2, HOXB13, GRHL2, and FOXA1 in whole ...

      Known for Prostate Cancer | Ctc Enumeration | Blood Patients | Prognostic Biomarker | Castrationresistant Rna
      KOL-Index: 14086

      BACKGROUND: Abiraterone acetate (AA) is an androgen biosynthesis inhibitor shown to prolong life in patients with castration-resistant prostate cancer (CRPC) already treated with chemotherapy. AA treatment results in dramatic declines in prostate-specific antigen (PSA) in some patients and no declines in others, suggesting the presence of molecular determinants of sensitivity in tumors.

      OBJECTIVE: To study the role of transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis ...

      Known for Abiraterone Acetate | Circulating Tumor Cells | Erg Status | Predictive Biomarker | Aa Treatment

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      Memorial Sloan Kettering Cancer Center, New York, NY; | Department of Medicine, Weill Cornell Medical College, New York, NY, USA | Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York | Memorial Sloan Kettering C

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.